14 Jun 2024

Precision Surgery Improving Outcomes for Cancer Patients

FluoGuide is a clinical-stage biotech company, elevating precision surgery with FG001, illuminating cancer cells during surgery to enhance outcomes for patients

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

LatestPress & news

30 May 2024 FluoGuide A/S publishes interim report for the period January – March 2024 News English Regulatory Listing Regulation Report Interim Q1 IR
27 May 2024 FluoGuide selects laser system for photothermal cancer therapy with FG001 News Corporate Information Other Corporate Information English IR

FluoGuideAn introduction

FluoGuide develops an imaging agent, applicable for maximizing surgical outcomes by making cancer fluorescent.

Successful application of FluoGuide’s products has the potential to lower system-wide healthcare costs because it will reduce the recurrence of cancer and lessen general surgical complications. Thereby, patients will require fewer readmissions to hospitals.

Project StatusRapidly progressing pipeline

FluoGuide’s pipeline consists of product candidates that has the potential to light up 80% of solid cancers. We continue to advance our pipeline for the benefit of cancer patients, society, and our shareholders. FluoGuide’s lead product, FG001, is furthest along in clinical development for aggressive brain cancer, currently in phase II trials targeting patients undergoing surgical removal of high-grade glioma. Additionally, FG001 is in phase II clinical development for head and neck cancer as well as lung cancer.


Phase I
Phase II
Phase III
Aggressive brain cancer (FGS)
Next milestone: Consolidated plans
Head & Neck cancer (FGS)
Next milestone: Consolidated plans
Lung cancer (FGS)
Next milestone: Consolidated plans
Aggressive brain cancer (PTT)
Next milestone: Consolidated plans
Follow-on pipeline
Next milestone: CTA submission

FluoGuideCalendar & events

Latest presentations

28 February 2024

Annual report interview with Redeye

28 February 2024

FluoGuide introduction with HC Andersen Capital

Subscribe for newsletter